Prognostic value and cost-effectiveness of different screening strategies for HLA antibodies prior to kidney transplantation

Clinical Transplantation

Volumn 26, Issue 4, 2012, Pages 644-656

  Ziemann, Malte ^a   Schönemann, Constanze ^b   Bern, Christina ^a   Lachmann, Nils ^b   Nitschke, Martin ^c   Fricke, Lutz ^c   Görg, Siegfried ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c NONE

Author keywords

Antibody mediated rejection; Graft survival; Human leukocyte antigens antibodies; Kidney transplantation; Pre sensitization; Solid phase techniques

Indexed keywords

HLA ANTIBODY;

ADULT; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; ECONOMIC ASPECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT SURVIVAL; HUMAN; INTERMETHOD COMPARISON; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; COST-BENEFIT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DONORS; YOUNG ADULT;

EID: 84865008014     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01615.x     Document Type: Article

References (25)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969: 280: 735.
2. Aubert V, Venetz J, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009: 70: 580.
3. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009: 70: 584.
4. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007: 7: 2371.
5. van den Berg-Loonen EM, Billen EVA, Voorter CEM et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008: 85: 1086.
6. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008: 85: 1200.
7. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010: 21: 1398.
8. Wahrmann M, Bartel G, Exner M et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009: 22: 982.
9. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol 2009: 162: 1.
10. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009: 87: 1681.
11. Morris GP, Phelan DL, Jendrisak MD, Mohanakumar T. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation. Hum Immunol 2010: 71: 268.
12. Riethmüller S, Ferrari-Lacraz S, Müller MK et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010: 90: 160.
13. Claas FHJ. Clinical relevance of circulating donor-specific HLA antibodies. Curr Opin Organ Transplant 2010: 15: 462.
14. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006: 67: 847.
15. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
16. Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, Lee J, El-Awar N, Alberú J. Natural human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008: 86: 1111.
17. Bartel G, Wahrmann M, Exner M et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008: 8: 41.
18. Andree H, Nickel P, Nasiadko C et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006: 17: 573.
19. Tang AH, Platt JL. Accommodation of grafts: implications for health and disease. Hum Immunol 2007: 68: 645.
20. Pratschke J, Weiss S, Neuhaus P, Pascher A. Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation. Transpl Int 2008: 21: 512.
21. Hönger G, Wahrmann M, Amico P, Hopfer H, Böhmig GA, Schaub S. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010: 89: 1471.
22. Bächler K, Amico P, Hönger G et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010: 10: 1254.
23. Glander P, Budde K, Schmidt D et al. The 'blood group O problem' in kidney transplantation-time to change? Nephrol Dial Transplant 2010: 25: 1998.
24. Colombo MB, Haworth SE, Poli F et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 2007: 72: 465.
25. Icks A, Haastert B, Gandjour A et al. Costs of dialysis-a regional population-based analysis. Nephrol Dial Transplant 2009: 25: 1647.